# eVOLVE-Lung02 (NCT05984277)

> A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05984277
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Non-small Cell Lung Cancer
- Interventions: Volrustomig; Pembrolizumab; Carboplatin; Paclitaxel; Pemetrexed
- Enrollment: 895
- Primary outcome: Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)
- Primary outcome: Overall Survival (OS), in PD-L1-negative participants.

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=evolve-lung02-nct05984277